Market News & Trends
Catalent Completes Acquisition of Gene Therapy Leader for $1.2 Billion
Catalent, Inc. recently announced it has completed the $1.2-billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.…
CureVac Enters Into Exclusive Sponsored Research Agreement
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, recently announced it has entered into a sponsored research agreement (SRA) with…
Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner
Precision Therapeutics Inc. recently announced its Helomics division has been selected as the preferred laboratory to provide laboratory services for the recently funded National Institute…
Saama Challenges Analytics Industry to Guarantee Data Platforms to Help Accelerate Drug Development
Saama Technologies, Inc. recently issued a call-to-action on Clinical Trials Day urging the analytics industry to commit to timely deployment of solutions for biopharmaceutical companies…
Owlstone Medical Enters Strategic Collaboration With Actelion
Owlstone Medical recently announced a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader…
Crinetics Pharmaceuticals Initiates Phase 1 Study for Treatment of Neuroendocrine Tumors
Crinetics Pharmaceuticals, Inc. recently announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics…
BioCryst’s Oral Drug Meets Primary Endpoint in Phase 3
BioCryst Pharmaceuticals, Inc. recently announced that the randomized (n=121), double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for the prevention of hereditary angioedema…
Yamo Pharmaceuticals Presents Results from Phase 2 Study
Yamo Pharmaceuticals, LLC recently announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD. A poster, titled An…
Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology
Elligo Health Research recently announced the launch of its innovative IntElligo Research Stack clinical technology. This standards-based technology platform, which powers the System of Accelerated…
ProBioGen & Vaccitech Sign License Agreement
ProBioGen AG and Vaccitech, Ltd. jointly announced signing a license agreement in which Vaccitech will gain access to ProBioGen’s proprietary technology platform based on the…